image_alt_text
10

Michael A. Caligiuri, MD

AIMBE College of Fellows Class of 2022
For discoveries in basic lymphocyte biology, and the translation into highly impactful applications for treating cancer.

Souped-up oncolytic virus warms up cold brain cancer tumors

Via Fierce Biotech | November 11, 2022

Among the hurdles to treating brain cancer is the fact that glioblastoma multiforme (GBM) cells burrow into brain tissue, which makes them difficult to wipe out with conventional treatments like surgery, radiation and chemotherapy. Moreover, they’re “cold” tumors, meaning they don’t contain immune cells that can easily be targeted with immunotherapies.

Now, scientists from City of Hope have found a way to warm up GBM, potentially unveiling a new therapeutic strategy. In a study published Nov. 10 in Nature, the researchers described how they packed two different therapies into a single oncolytic virus—a virus that is used to destroy cancer cells—to hit GBM from multiple angles. The survival time doubled from around 18 days to 40 in half the mice that received the treatment… Continue reading.

...

Novel Immunotherapy Developed by City of Hope Could Provide New Treatment Model for SARS-CoV-2 Patients

Via BioSpace | May 20, 2022

City of Hope researchers have engineered an immunotherapy using natural killer cells with a specific molecule that can target the SARS-CoV-2 virus’ spike protein, providing a novel therapeutic pathway for the treatment of COVID-19 and other infections that include the spike protein, according to a study published in Nature Communications. The research adds to City of Hope’s leadership in using CAR T cell therapy, natural killer cells and other immunotherapies to help find better treatments against cancer and other diseases.

“The importance of this off-the-shelf therapy is that one does not need to use one’s own cells — the cells can be frozen and ready to go, locally or shipped anywhere around the world,” said Michael Caligiuri, M.D., president of City of Hope National Medical Center, the Deana and Steve Campbell Physician-in-Chief Distinguished Chair and one of the study’s authors… Continue reading.

...

Dr. Michael Caligiuri Elected to the 2022 Class of the AIMBE College of Fellows

Via AIMBE | February 18, 2022

WASHINGTON, D.C. — The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of Michael A. Caligiuri, MD, President, Hematology, City of Hope to its College of Fellows. Dr. Caligiuri was nominated, reviewed, and elected by peers and members of the AIMBE College of Fellows for discoveries in basic lymphocyte biology, and the translation into highly impactful applications for treating cancer.

The College of Fellows is comprised of the top two percent of medical and biological engineers in the country. The most accomplished and distinguished engineering and medical school chairs, research directors, professors, innovators, and successful entrepreneurs comprise the College of Fellows. AIMBE Fellows are regularly recognized for their contributions in teaching, research, and innovation. AIMBE Fellows have been awarded the Nobel Prize, the Presidential Medal of Science and the Presidential Medal of Technology and Innovation, and many also are members of the National Academy of Engineering, National Academy of Medicine, and the National Academy of Sciences… Continue reading.

...